Skip to content

A single-center clinical study on the efficacy and safety of Yanghe Decoction combined with hot compress in the treatment of benign intraductal papilloma of the breast in women (Yang deficiency and cold coagulation syndrome)

A Single-Center Clinical Study on the Efficacy and Safety of Yanghe Decoction Combined with Heat Fomentation Pack for Treating Benign Intraductal Papilloma of the Breast in Women (Yang Deficiency with Cold Aggregation Syndrome)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001736
Enrollment
Unknown
Registered
2026-07-13
Start date
2026-07-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female benign intraductal papilloma of the breast duct

Interventions

treatment group:Yanghe Decoction combined with hot compresses
control group:active surveillance

Sponsors

Chongqing Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Young and middle-aged women of childbearing age (aged 18 to 55); 2. Diagnosed with intraductal breast lesions by breast color Doppler ultrasound, and classified by BI-RADS as strictly category 3 or 4a (category 4a requires confirmation by MDT); the patient clearly expressed a refusal of surgical treatment (this intention must be clearly recorded in the medical record and reconfirmed during the informed consent process); only patients who have been unanimously assessed by MDT as being acceptable for short-term observation or non-surgical treatment can be included. 3. Complete clinical data; 4. Meet the diagnostic criteria of the TCM syndrome of Yang deficiency and cold coagulation; 5. Voluntarily participate in the trial, have signed the informed consent approved by the ethics committee, and cooperate with this research project; 6. Have good compliance, take the prescribed medications as per the research regulations and undergo follow-up examinations.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors; 2. Exclude those who are planning to conceive, have a conception plan within the past three months, are pregnant, or are in the lactation period with breast diseases; 3. Exclude those who have undergone breast surgery due to breast diseases in the past; 4. Exclude those with severe systemic diseases, who cannot express their own will, those with mental disorders, or those with hysteria; 5. Exclude those with allergic constitution, who are allergic to external medications or external dressings; 6. Exclude those who have taken drugs that may affect the observation indicators of this study within the recent period (about one month before enrollment) and cannot stop using them.

Design outcomes

Primary

MeasureTime frame
Rate of lesion progression;Surgical delay rate;

Secondary

MeasureTime frame
Simplified McGill Pain Questionnaire (SF-MPQ);Amount of nipple discharge;Breast Mass Score;Traditional Chinese Medicine Syndrome Score;

Countries

China

Contacts

Public ContactGang Lyu

Chongqing Traditional Chinese Medicine Hospital

cqszyyrxklg@163.com18696708566

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026